Compare KLTR & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KLTR | PYXS |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.6M | 172.2M |
| IPO Year | 2021 | 2021 |
| Metric | KLTR | PYXS |
|---|---|---|
| Price | $1.47 | $2.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $3.00 | ★ $7.00 |
| AVG Volume (30 Days) | 477.0K | ★ 543.4K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.90 | 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,854,000.00 | $13,858,000.00 |
| Revenue This Year | $2.96 | N/A |
| Revenue Next Year | $4.96 | $7,043.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.20 | N/A |
| 52 Week Low | $1.06 | $0.97 |
| 52 Week High | $2.27 | $5.55 |
| Indicator | KLTR | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 59.77 | 73.44 |
| Support Level | $1.39 | $1.28 |
| Resistance Level | $1.63 | $3.89 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 72.86 | 77.31 |
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.